These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21155613

  • 21. Patient treatment preferences for osteoporosis.
    Fraenkel L, Gulanski B, Wittink D.
    Arthritis Rheum; 2006 Oct 15; 55(5):729-35. PubMed ID: 17013870
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 24. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
    Quesada-Gómez JM, Muschitz C, Gómez-Reino J, Greisen H, Andersen HS, Dimai HP.
    Osteoporos Int; 2011 Sep 16; 22(9):2529-37. PubMed ID: 21052638
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects.
    Liu Y, Yang C, Li Z, Zhou J, Lv Y, Zhang Y, Zeng F, Shi S.
    Clin Ther; 2014 Jun 01; 36(6):940-52. PubMed ID: 24793535
    [Abstract] [Full Text] [Related]

  • 34. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.
    Thorsteinsson AL, Vestergaard P, Eiken P.
    Arch Osteoporos; 2015 Jun 01; 10():35. PubMed ID: 26427867
    [Abstract] [Full Text] [Related]

  • 35. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
    Ohta H, Hamaya E, Taketsuna M, Sowa H.
    Curr Med Res Opin; 2015 Jan 01; 31(1):85-94. PubMed ID: 25299349
    [Abstract] [Full Text] [Related]

  • 36. Summaries for patients. Parathyroid hormone (1-84) and risk for spinal fractures in women with osteoporosis.
    Ann Intern Med; 2007 Mar 06; 146(5):I20. PubMed ID: 17339614
    [No Abstract] [Full Text] [Related]

  • 37. Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism.
    Rubin MR, Cusano N, Yin S, Tokareva E, Ayodele O, Finkelman RD.
    Endocr Pract; 2024 Mar 06; 30(3):200-208. PubMed ID: 38086524
    [Abstract] [Full Text] [Related]

  • 38. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.
    Gittoes N, Rejnmark L, Ing SW, Brandi ML, Björnsdottir S, Hahner S, Hofbauer LC, Houillier P, Khan AA, Levine MA, Mannstadt M, Shoback DM, Vokes TJ, Zhang P, Marelli C, Germak J, Clarke BL.
    BMC Endocr Disord; 2021 Nov 20; 21(1):232. PubMed ID: 34801015
    [Abstract] [Full Text] [Related]

  • 39. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
    Dobnig H.
    Expert Opin Pharmacother; 2004 May 20; 5(5):1153-62. PubMed ID: 15155114
    [Abstract] [Full Text] [Related]

  • 40. Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84).
    Luna-Cabrera F, Justicia-Rull EA, Caricol-Pérez MP, Soler-Vizán E, Mesa-López CM, Ruiz-Ruiz MA, De La Torre-López LE.
    Minerva Med; 2012 Apr 20; 103(2):103-10. PubMed ID: 22513515
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.